您的位置: 首页 > 农业专利 > 详情页

Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
专利权人:
William J. McBride;David M. Goldenberg;Edmund A. Rossi;Chien-Hsing Chang
发明人:
Chien-Hsing Chang,David M. Goldenberg,William J. McBride,Edmund A. Rossi
申请号:
US13178092
公开号:
US08158129B2
申请日:
2011.07.07
申请国别(地区):
US
年份:
2012
代理人:
摘要:
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充